ACAT1 and neoplasm: Tumor puncture samples from 29 patients with NSCLC treated with immunotherapy were collected, and ACAT1 antibody-based IHC revealed that patients with a poor immunotherapy response (PD, disease progression) had significantly higher ACAT1 levels than those who responded well to immunotherapy (SD or PR, disease stability or remission) (Figure 2M and Supplemental Table 4).